PHC Corporation's Indonesia Subsidiary Starts Full-scale Operations

KUALA LUMPUR, Nov 14 (Bernama) -- Tokyo-based PHC Corporation’s Biomedical Division, provider of PHCbi-branded products, announced a new subsidiary in Indonesia established in March for sales and servicing of equipment including area in life science has commenced business activities, after completing relevant requirements such as securing a distribution licence for medical devices.

The company, PT PHC Sales Indonesia (PHCSI), a subsidiary of Singapore-based SciMed (Asia) Pte Ltd (SciMed) which is in turn wholly owned by PHC Holdings Corporation (PHCHD), will further reinforce the foundation and facilitate growth of the Biomedical Division’s life science business in Indonesia.

PHC Corporation President, Representative Director and Biomedical Division Director, Nobuaki Nakamura said the new company in Indonesia has started full-scale operations.

“In order to reinforce the Biomedical Division’s life science business foundations in Southeast Asia with high market growth potential, we have put the best efforts into establishing a new sales company fully prepared for business launch in Indonesia, following 100 per cent ownership acquisition of SciMed this past June.

“In the coming years, PHCSI along with SciMed will be well-positioned to function as an important operating location in Asia for PHC Group and further expand existing business in Indonesia and promote full-scale entry into advanced medical treatments such as cell and gene therapies,” he said in a statement.

The life science equipment market for the Asia Pacific region is poised for solid growth, reflecting an increase in research and development investment for biopharmaceuticals and growth in new medical institutions.

The Biomedical Division, through fellow PHCHD subsidiary SciMed, is already conducting sales and service for life science equipment in Southeast Asia, India and Oceania.

PT PHC Indonesia (PHCI), a manufacturing subsidiary of PHCHD, also operates in the region as a secondary manufacturing base after Japan to respond to global demand for high-quality products such as biomedical freezers, pharmaceutical refrigerators, and carbon dioxide incubators.

The establishment of PHCSI will now allow the Biomedical Division to create a sales and service platform in Indonesia, reaching potential new customers and expanding its distributor network while strengthening customer service.

By closely monitoring this market, the Biomedical Division will be better positioned to fulfil customer needs, develop new business opportunities in Indonesia, and accelerate business growth by utilising its high manufacturing capabilities to deliver high-quality products.

-- BERNAMA